Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone919-237-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.18 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its earnings results on Wednesday, August, 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.16. The firm earned $2.42 million during the quarter, compared to the consensus estimate of $1.16 million. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What price target have analysts set for AERI?
10 Wall Street analysts have issued twelve-month target prices for Aerie Pharmaceuticals' shares. Their forecasts range from $64.00 to $105.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $79.10 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Aerie reported mixed results for the fourth quarter. Though earnings missed estimates, Rhopressa sales comfortably beat estimates and doubled sequentially. The solid uptake in prescription volumes should propel Rhopressa sales further, as glaucoma is one of the largest segments in the global ophthalmic market. The FDA approval of its second candidate, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan has further boosted the company’s portfolio. Shares have underperformed the industry in the past six months. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta among others." (3/15/2019)
- 2. Mizuho analysts commented, "We see this guidance as conservative and we believe there is a reasonable chance for Aerie to outperform in 2019. We currently model FY19 revenue of ~$120mn. Rocklatan is expected to launch in the U.S. in early May with a fully trained salesforce. Keep in mind: insurance coverage pickup could be faster as contracts with payers will already be in place (from Rhopressa)." (3/13/2019)
- 3. Cowen Inc analysts commented, "An abstract for HS-110 combo with checkpoint inhibitor nivolumab was released. The interim data indicated that HS-110 combo with nivolumab leads to meaningful benefit consistent with earlier results. We expect that the presentation at 2019 will contain updated results with a later cut-off date." (2/27/2019)
Has Aerie Pharmaceuticals been receiving favorable news coverage?
News headlines about AERI stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next several days.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA) and Audentes Therapeutics (BOLD).
What other stocks do shareholders of Aerie Pharmaceuticals own?
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
- Mr. Thomas A. Mitro, Pres & COO (Age 61)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
- Ms. Jessica Crespo CPA, Director of Accounting
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.06%), Foresite Capital Management III LLC (4.29%), Partner Fund Management L.P. (4.17%), Foresite Capital Management II LLC (3.68%), Bank of New York Mellon Corp (3.23%) and Jennison Associates LLC (2.60%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which institutional investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Partner Fund Management L.P., Orbimed Advisors LLC, Millennium Management LLC, Jennison Associates LLC, Columbus Circle Investors, Citigroup Inc. and Polar Capital LLP. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which institutional investors are buying Aerie Pharmaceuticals stock?
AERI stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Sectoral Asset Management Inc, Norges Bank, Foresite Capital Management IV LLC, Foresite Capital Management III LLC, Foresite Capital Management II LLC, Candriam Luxembourg S.C.A. and Eversept Partners LP. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $46.11.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $2.10 billion and generates $24.18 million in revenue each year. The company earns $-232,570,000.00 in net income (profit) each year or ($4.65) on an earnings per share basis.
What is Aerie Pharmaceuticals' official website?
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
